Description
How It Works
Kisspeptin-10 acts at the hypothalamus by stimulating GnRH (Gonadotropin-Releasing Hormone) release. This drives downstream signaling through the HPG axis, influencing LH and FSH release, and ultimately supporting testosterone and estrogen regulation.
| Pathway |
Primary Effect |
| Hypothalamic activation |
Stimulates GnRH release |
| HPG axis support |
Supports LH and FSH signaling |
| Hormonal balance |
Supports endogenous testosterone and estrogen regulation |
| Libido signaling |
Associated with sexual response and behavioral pathways |
Results and Outcomes
Kisspeptin-10 is used where the goal is improved hormonal signaling, libido support, and reproductive-axis regulation. It is typically positioned for short-cycle use to stimulate response without desensitization.
| Expected Outcome |
Practical Effect |
| Hormonal signalling |
Supports upstream endocrine activation |
| Libido support |
Supports sexual response and drive |
| Cycle regulation |
Supports menstrual and ovulatory signaling |
| HPG-axis support |
Supports natural hormone production pathways |
Dosage Protocol
Total strength: 2 mg / 2 mL
Concentration: 1000 mcg/mL
Cartridge system: 200 units
Per unit: 10 mcg
Cycle guidance: Use for 2–4 weeks, then pause for 4 weeks before repeating
Dosage Scale (Pen System)
| Units |
Dose |
Volume |
| 5 units |
50 mcg |
0.05 mL |
| 10 units |
100 mcg |
0.10 mL |
| 15 units |
150 mcg |
0.15 mL |
| 20 units |
200 mcg |
0.20 mL |
Recommended Dosage
| Use Case |
Dose |
Frequency |
Pen Equivalent |
| Ovulation support / Cycle regulation (women) |
100 mcg |
2–3 times per week |
10 units per dose |
| Hypothalamic amenorrhea (cycle loss) |
100–200 mcg |
3–5 times per week |
10–20 units per dose |
| Libido support / Sexual response (women) |
50–100 mcg |
2–3 times per week |
5–10 units per dose |
| Testosterone / HPG-axis support (men) |
100–200 mcg |
3 times per week |
10–20 units per dose |
| Libido support / Sexual response (men) |
100 mcg |
3–5 times per week |
10 units per dose |
Notes
| Guidance |
Detail |
| Cycle structure |
Use for 2–4 weeks, then pause for 4 weeks to avoid tachyphylaxis |
| Frequency |
Intermittent dosing preferred over daily continuous use |
| Positioning |
Best used as a signaling peptide rather than continuous hormone support |
| Use style |
Short-cycle activation followed by recovery phase |
Warnings
| Warning |
Detail |
| General |
Not suitable for people under the age of 18 / during pregnancy / while breastfeeding |
Related Products
| Product |
Use Case |
| PT-141 |
Direct libido and sexual response support |
| HCG |
Downstream hormonal support pairing |
| CJC-1295 / Ipamorelin |
Hormonal and recovery support |
| Retatrutide |
Metabolic and appetite control support |